Skip to main content

August 2018

 

Clinical courses

 

Clinical courses

Opportunity for M.Pharm, M.Sc in Early Career Research Project at DPU

Dr. D. Y. Patil Vidyapeeth, Pune, comprising of Padmashree Dr. D. Y. Patil Medical College, Hospital and Research Centre, Pimpri, Pune, was accorded the status of University under Section 3 of the UGC Act, 1956, vide Notification No. F.9-39/2001-U.3 dated 11th January 2003 of the Government of India, Ministry of Human Resource Development, Department of Secondary & Higher Education, New Delhi, and (ii) Notification No.F6-9/2003 (CPP-I) dated 24/01/2003 by the University Grants Commission, New Delhi.

Applications are invited on plain paper from eligible candidates along with biodata and copies of certificates in support of age, qualification and experience for Junior Research Fellow.

Job for Production Officer at Envision Scientific | 10 posts

Envision Scientific is a company involved in research, development and manufacturing of innovative products and methods for treatment of cardiovascular disease. Envision Scientific is a company pioneering in the development of Nanotechnology based applications for delivery. Envision Scientific has developed a novel polymer free nanocarrier based drug delivery system in its R&D Lab.

Post : Officer - Production

Vacancy for Professor, Lecturer at Berhampur University

The Berhampur University came into existence on 2nd January 1967 being inaugurated by Dr. A.N. Khosla, the then Governor of Orissa and the first Chancellor of the University. The University was later shifted to the present site known as Bhanja Bihar, named after the celebrated poet of Orissa Kabisamrat Upendra Bhanja. Spreading over an area of about two hundred fifty acres the university is twelve kilometres and 5 kilometers away from the Berhampur City and Sea-beach of Gopalpur respectively.

Vacancy for M.Pharm, B.Pharm as Junior Research Fellow at Central University of Rajasthan

The Central University of Rajasthan has been established by an Act of Parliament, the Central Universities Act 2009. The University started working temporarily from Jaipur and introduced two PG programmes in 2009-10, namely M.Sc./M.A. Statistics (Actuarial) and M.Sc. Tech Mathematics in collaboration with Malaviya National Institute of Technology(MNIT), Jaipur.

Post : JRF

IICB invites application for Research Associate | Ph.D in Life Science

IICB Institute was established in 1935 as the first non official centre in India for biomedical research and was included within the aegis of CSIR in 1956. IICB today is engaged in research on diseases of national importance and biological problems of global interest, employing sophisticated state-of-the-art technology in keeping with the rapid and unprecedented momentum that life science research has gained globally over the last 50 years. IICB is one of the major institutes in India which initiated, right from its inception, multidisciplinary concerted efforts for conducting basic research on infectious diseases, specifically leishmaniasis and cholera, along with the development of technologies for the diagnosis, immunoprophylaxis, and chemotherapy of the diseases.

Post : Research Associate - I

Applications are invited for Junior Research Fellow at Central University of Jammu

The Central University of Jammu came into existence on August 08, 2011, with the appointment of  the first Vice-Chancellor. It was established by the Central Universities Act, 2009 (Act No.25 of 2009 read with the Central Universities Act, 2009).  The first academic session (2011-2012) commenced with three Post Graduate courses in English, Economics and Applied Mathematics at Temporary Academic Block-I (TAB-I) at Sidhra bypass road, Jammu. In the next academic session (2012-2013),five PG Courses were added: Computer Science, Educational Studies, Environmental Sciences, Human Resource Management and Travel & Tourism Management in Temporary Academic Block (TAB-II) at Sainik Colony Extension.

Post : Junior Research Fellow (JRF)

Job for JRF, SRF, Project Assistant at IICB

IICB Institute was established in 1935 as the first non official centre in India for biomedical research and was included within the aegis of CSIR in 1956. IICB today is engaged in research on diseases of national importance and biological problems of global interest, employing sophisticated state-of-the-art technology in keeping with the rapid and unprecedented momentum that life science research has gained globally over the last 50 years. IICB is one of the major institutes in India which initiated, right from its inception, multidisciplinary concerted efforts for conducting basic research on infectious diseases, specifically leishmaniasis and cholera, along with the development of technologies for the diagnosis, immunoprophylaxis, and chemotherapy of the diseases.

Johnson & Johnson looking for District Account Manager

Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson. We embrace innovation—bringing ideas, products and services to life to advance the health and well-being of people around the world. We believe in collaboration, and that has led to breakthrough after breakthrough, from medical miracles that have changed lives, to the simple consumer products that make every day a little better. Our over 125,000 employees in 60 countries are united in a common mission: To help people everywhere live longer, healthier, happier lives.

Post : District Account Manager

Work as Trainee Analyst, Analyst, Senior Analyst at GVW Technologies

Global Value Web connects companies across the globe for unique opportunities in products, services and talent. It enables global supply chains services. Our focus is on industry segments such as Energy and Health. GVW completes five years of Superiority client service in the year 2014. Global Value Web is a service provider for M/s. Johnson & Johnson (Janssen Pharmaceutical), a Top 5 Global Pharma Enterprise.

Post : Trainee Analyst / Analyst / Sr.Analyst

Novartis announced the global Phase III SOLAR-1 trial evaluating the investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) has met the primary endpoint showing an improvement in progression-free survival (PFS). SOLAR-1 is evaluating BYL719 in combination with fulvestrant compared to fulvestrant alone in postmenopausal women and men with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) PIK3CA-mutant advanced or metastatic breast cancer that progressed on or following aromatase inhibitor treatment with or without a CDK4/6 inhibitor